Important Immunotherapy Updates in Non-Small Cell Lung Cancer

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct strengths and limitations. IV administration offers established dosing precision, flexibility for complex regimens, and familiarity across oncology practices, but it is often associated with longer chair time, higher staffing demands, and increased use of infusion resources. In contrast, SC injections provide a more streamlined approach, with shorter administration times and reduced need for infusion infrastructure. Emerging evidence suggests that SC formulations can meaningfully decrease health care utilization, improve clinic efficiency, and enhance patient convenience without compromising clinical outcomes. For patients, SC delivery may translate into less time in the clinic and a more favorable treatment experience, while practices may benefit from improved throughput and optimized resource allocation. Together, these considerations highlight the growing value of SC formulations in evolving oncology care models.

Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic therapy focused on disease control and survival in advanced stages.

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus chemotherapy as a standard-of-care option based on improved pathologic response and event-free survival outcomes.

How EGFR, ALK and PD-L1 biomarker results shape neoadjuvant lung cancer therapy—and what CheckMate-816 means for survival.

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data.

Experts weigh neoadjuvant vs adjuvant immunotherapy in resectable lung cancer, balancing PD‑L1, pCR, surgery timing, and toxicity.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity.

Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.

Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.

Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.